2228 Stock Overview

An investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. More details

2228 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 38.8% below our estimate of its fair value

Revenue is forecast to grow 39.45% per year

Revenue grew by 28.2% over the past year

Risk Analysis

Highly volatile share price over the past 3 months compared to the Hong Kong market

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

Capture your thoughts, links and company narrative

XtalPi Holdings Limited Competitors

Genscript Biotech

SEHK:1548

HK$20.9b

WuXi XDC Cayman

SEHK:2268

HK$38.3b

WuXi Biologics (Cayman)

SEHK:2269

HK$69.9b

Frontage Holdings

SEHK:1521

HK$3.4b

Price History & Performance

Summary of share price highs, lows and changes for XtalPi Holdings
Historical stock prices
Current Share Price	HK$5.55
52 Week High	HK$14.18
52 Week Low	HK$3.05
Beta	0
1 Month Change	37.38%
3 Month Change	-57.95%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-57.44%

Recent updates

Shareholder Returns

	2228	HK Life Sciences	HK Market
7D	40.9%	1.6%	-0.5%
1Y	n/a	-32.2%	19.9%

Return vs Industry: Insufficient data to determine how 2228 performed against the Hong Kong Life Sciences industry.

Return vs Market: Insufficient data to determine how 2228 performed against the Hong Kong Market.

Price Volatility

Is 2228's price volatile compared to industry and market?
2228 volatility
2228 Average Weekly Movement	20.4%
Life Sciences Industry Average Movement	12.1%
Market Average Movement	8.8%
10% most volatile stocks in HK Market	18.6%
10% least volatile stocks in HK Market	4.1%

Stable Share Price: 2228's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: Insufficient data to determine 2228's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	760	Jian Ma	www.xtalpi.com

XtalPi Holdings Limited, an investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. The company’s drug discovery solutions cover the whole drug discovery and research process, including target validation, hit identification, lead generation, lead optimization, and PCC nomination covering various modalities, which comprise small molecules, antibodies, peptides, ADC, and PROTAC. Its intelligent automation solutions focus on AI- and automation-enabled novel drug and materials discovery and research.

XtalPi Holdings Limited Fundamentals Summary

How do XtalPi Holdings's earnings and revenue compare to its market cap?
2228 fundamental statistics
Market cap	HK$18.91b
Earnings (TTM)	-HK$2.71b
Revenue (TTM)	HK$210.04m

90.0x

P/S Ratio

-7.0x

P/E Ratio

Is 2228 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2228 income statement (TTM)
Revenue	CN¥197.08m
Cost of Revenue	CN¥104.80m
Gross Profit	CN¥92.29m
Other Expenses	CN¥2.63b
Earnings	-CN¥2.54b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.75
Gross Margin	46.83%
Net Profit Margin	-1,287.98%
Debt/Equity Ratio	1.6%

How did 2228 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 00:05
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

XtalPi Holdings Limited is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yu Wu	CMB International Securities Limited
Yue-Kwong Lui	Jefferies LLC

XtalPi Holdings SHSC:2228 Stock Report